ClinicalTrials.gg
CompletedNCT02502734Updated Nov 17, 2017Results posted

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

A Phase 3 interventional study of Fluticasone furoate and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in Denmark. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
23rd of 40
60 · median 102
Started
2015
with 2 others
Phase 3
14 of 40
none open now
Registered
29th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 23rd largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 29th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study will be conducted to evaluate the effect of once daily treatment with fluticasone furoate (FF) on lower leg growth in pediatric subjects with persistent asthma by using knemometry. Approximately 65 paediatric asthmatic subjects, aged 5 to 11 years (inclusive), will be screened to achieve 60 randomised and 50 evaluable subjects. Subjects meeting the eligibility criteria will enter the 2 week run-in period. After completing run-in period, each subject will be randomly allocated to one of two treatment sequences: inhaled fluticasone furoate followed by placebo or placebo followed by inhaled fluticasone furoate. Each treatment will be administered via the ELLIPTA™ dry powder inhaler. The two treatment periods will be separated by a two-week wash-out period. Subjects completing two treatment period will enter into 7 days follow-up period. ARNUITY™ ELLIPTA (FF) is approved in the US for adults and adolescents aged 12 and above.

ARNUITY and ELLIPTA are a registered trademarks of the GlaxoSmithKline group of companies.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • inhaled corticosteroids
  • pediatric subjects
  • asthma
  • fluticasone furoate
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 5 years to less than 12 years at Visit 1. At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.
  • Male or pre-menarchial female subjects.
  • Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).
  • Normal range for their height and weight. Weight and height measurements should fall within the percentile range 3-97% of normal values for age according to Danish growth charts.
  • Have a documented diagnosis of persistent asthma, as defined by the National Institutes of Health for at least 3 months prior to the Screening Visit.
  • A pre-bronchodilatory forced expiratory flow in 1 second () at Visit 1 (Screening) >=80% predicted. There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement.
  • Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide \<=400 micrograms (mcg) total daily dose). There must be no ICS use within 2 weeks of Visit 1 (Screening).
  • Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.
  • Written from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement. The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC). (2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis. (3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.

Exclusion criteria

Exclusion Criteria:

  • A history of life-threatening asthma defined for this protocol as an asthma episode that required intubation, hypercapnea requiring non-invasive ventilatory support, respiratory arrest, hypoxic seizures or asthma-related syncopal episode(s).
  • Subjects with a history of asthma exacerbation requiring the use of systemic (tablets, suspension, or injection) for at least 3 days or a depot corticosteroid injection or emergency room attendance (within 3 months) or requiring hospitalization for asthma (within 6 months) prior to screening.
  • Significant, non-reversible active pulmonary disease (e.g. cystic fibrosis, bronchiectasis, tuberculosis).
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any fracture in the leg to be measured within 6 months prior to the screening visit.
  • Any metabolic disorders or other diseases that may impact on normal growth patterns.
  • No major surgery requiring general anaesthesia for at least 3 months prior to the screening visit.
  • No febrile illnesses with temperature >39 degree celsius for more than five consecutive days within the week preceding the Screening Visit.
  • Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.
  • Clinical visual evidence of candidiasis at Visit 1 (Screening).
  • Use of any of the prohibited medications listed in protocol.
  • Strenuous physical exercise within 3 hours of Visit 1 (Screening)
  • Drug allergies: Any adverse reaction including immediate or delayed to any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the ELLIPTA Inhaler (i.e., lactose, FF).
  • Milk Protein Allergy: History of severe milk protein allergy.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.
  • Unable to use the ELLIPTA inhaler and peak flow meter correctly.
  • An affiliation with the Investigator site: the parents/guardians or child is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
  • The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being.
  • Children in care: Children who are wards of the government or state are not eligible for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Sequence 1: Fluticasone furoate 50 μg and then placebo

    Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.

    Drug: Fluticasone furoate · Drug: Placebo · Drug: Salbutamol

  • Experimental
    Sequence 2: Placebo and then fluticasone furoate 50 μg

    Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.

    Drug: Fluticasone furoate · Drug: Placebo · Drug: Salbutamol

Interventions

  • FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.

  • DrugPlacebo

    Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.

  • Salbutamol will be provided as a inhaler.

06

What researchers measure

Primary outcomes

  1. Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry.

    Lower leg growth rate was assessed in growth population as change in the lower leg length from start to end of each 2-week period, divided by time interval (number of days) between the two measurements, multiplied by 7. The Growth Population is defined as the Intent-To-Treat (ITT) population excluding participants having any of the following: did not fulfill growth-specific criteria; did not have growth assessment(s) at any defined time point; withdrawal from study due to adverse events related to major trauma to the legs, major surgery, or severe dehydration; received protocol prohibited medications that may affect short term growth, prior to randomization and during the study; protocol deviations defined in exclusion criteria for growth population. ITT Population consists of all randomized participants who received at least one dose of study drug.

    Time frame: Over a two week (14 day) treatment period for FF 50mcg OD and Placebo respectively.

Secondary outcomes

  1. Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect. Number of participants with AEs and SAEs have been presented. Two participants randomized to Sequence 1 (Placebo/FF), were treated with placebo in Period 1; however, neither received FF in Period 2, due to premature withdrawal.

    Time frame: From the start of study treatment until follow-up (assessed up to 54 days)

07

Results

Posted Jul 29, 2016

Participant flow

Study consisted of run-in period of two-weeks followed by two treatment periods of 14 days each (+/- 4 days) separated by a 14-day washout period and a follow-up visit of approximately 7 days post last dose. The total participation time in the study was approximately 9 Weeks.

Double-blind Treatment Period 1
Participant flow — Double-blind Treatment Period 1
MilestonePlacebo Followed by Fluticasone FuroateFluticasone Furoate Followed by Placebo
Started3030
Completed2930
Not completed10
Withdrew: Adverse event10
Washout Period
Participant flow — Washout Period
MilestonePlacebo Followed by Fluticasone FuroateFluticasone Furoate Followed by Placebo
Started2930
Completed2830
Not completed10
Withdrew: Adverse event10
Double-blind Treatment Period 2
Participant flow — Double-blind Treatment Period 2
MilestonePlacebo Followed by Fluticasone FuroateFluticasone Furoate Followed by Placebo
Started2830
Completed2830
Not completed00

Outcome measures

PrimaryMean Growth Rate in Lower-leg Growth, as Determined by Knemometry.

Lower leg growth rate was assessed in growth population as change in the lower leg length from start to end of each 2-week period, divided by time interval (number of days) between the two measurements, multiplied by 7. The Growth Population is defined as the Intent-To-Treat (ITT) population excluding participants having any of the following: did not fulfill growth-specific criteria; did not have growth assessment(s) at any defined time point; withdrawal from study due to adverse events related to major trauma to the legs, major surgery, or severe dehydration; received protocol prohibited medications that may affect short term growth, prior to randomization and during the study; protocol deviations defined in exclusion criteria for growth population. ITT Population consists of all randomized participants who received at least one dose of study drug.

Time frame:
Over a two week (14 day) treatment period for FF 50mcg OD and Placebo respectively.
Reported as:
Least squares mean · millimeter per week
Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry.
millimeter per weekPlaceboFluticasone Furoate
Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry.0.3638 ± 0.027930.3118 ± 0.02793
Statistical analysis
  • Placebo vs Fluticasone Furoate · ANCOVA · Mean difference (final values): -0.0520 · 95% CI -0.1217 to 0.0176Analysis performed using ANCOVA with covariates period-level baseline and subject-level baseline lower-leg length, age, gender, treatment and period.
SecondaryNumber of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect. Number of participants with AEs and SAEs have been presented. Two participants randomized to Sequence 1 (Placebo/FF), were treated with placebo in Period 1; however, neither received FF in Period 2, due to premature withdrawal.

Time frame:
From the start of study treatment until follow-up (assessed up to 54 days)
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).
ParticipantsPlaceboFluticasone Furoate
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).157

Adverse events

Collected over SAEs and non-serious AEs were collected from start of study medication through the Study Phase (7 weeks post-dose) and assessed up to 54 days. AEs reported during the wash-out and follow-up period are considered post-treatment and are not presented.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/60 (1.7%)15/60 (25%)
Fluticasone Furoate—0/58 (0%)7/58 (12.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboFluticasone Furoate
AsthmaRespiratory, thoracic and mediastinal disorders1/600/58
Most frequent other events
Most frequent other events
EventPlaceboFluticasone Furoate
HeadacheNervous system disorders8/603/58
NasopharyngitisInfections and infestations5/604/58
CoughRespiratory, thoracic and mediastinal disorders3/602/58
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/602/58
PyrexiaGeneral disorders2/600/58

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Furoate and Placebo in Any of the Two Sequences
Mean8.7 ± 1.53
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Furoate and Placebo in Any of the Two Sequences
Female24
Male36
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fluticasone Furoate and Placebo in Any of the Two Sequences
Asian - Central/South Asian Heritage1
White - White/Caucasian/European Heritage59
08

Study locations

1 site
  • GSK Investigational Site
    Randers, 8900, Denmark
09

References and documents

Publications

  • Wolthers OD, Stone S, Bareille P, Tomkins S, Khindri S. Knemometry Assessment of Short-term Growth in Children With Asthma Receiving Fluticasone Furoate for 2 Weeks: A Randomized, Placebo-controlled, Crossover Trial. Clin Ther. 2017 Jun;39(6):1191-1199. doi: 10.1016/j.clinthera.2017.04.011. Epub 2017 May 22. Erratum In: Clin Ther. 2017 Sep;39(9):1904. doi: 10.1016/j.clinthera.2017.08.007. PubMed 28545804 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Dec 2015, 3 months.

Results were first posted in Jul 2016, 7 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 3 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2015
First posted
Jul 20, 2015
StartActual
Sep 7, 2015
Primary completionActual
Dec 21, 2015
CompletionActual
Dec 21, 2015
Results first posted
Jul 29, 2016
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02502734
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 20, 2015
Start date
Sep 7, 2015
Primary completion
Dec 21, 2015
Completion
Dec 21, 2015
Results posted
Jul 29, 2016
Last update
Nov 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion